Business
Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting
LP-184 demonstrated anti-tumor activity in brain metastases cell models from lung, skin, and breast cancers. Brain metastases in the U.S. can occur in 10-30%
About this update from Lantern Pharma Inc.
[{"type":"text","content":"LP-184 demonstrated anti-tumor activity in brain metastases cell models from lung, skin, and breast cancers. Brain metastases in the U.S. can occur in 10-30% of all cancer cases and are diagnosed in over 100,000 patients each year. Data supports continued development of LP-184 in CNS cancer indications where there is an urgent and unmet clinical need. DALLAS, March 14, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"A.I.\") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present positive preclinical data on the in vitro efficacy of its drug candidate LP-184 in brain metastases (mets) at the American Association of Cancer Research (AACR) annual meeting, April 8-13th, 2022, held in New Orleans, Louisiana.\n\n \n \n \n \n \n \n\n \nLP-184 is a small molecule drug candidate and next generation acylfulvene that preferentially damages DNA in cancer cells that overexpress certain biomarkers and is therefore lethal in tumors that harbor mutations or deficiencies in DNA repair pathways. LP-184 has already been demonstrated preclinically to have potent efficacy in several targeted central nervous system (CNS) cancer indications, including glioblastoma multiforme (GBM) and atypical teratoid rhomboid tumors (ATRT). The development promise for LP-184 in these indications is strengthened by LP-184's favorable blood brain barrier (BBB) permeability. LP-184 has also demonstrated potent tumor cell killing capabilities in vitro and in animal xenografts of tumors such as lung, breast, melanoma and colon, many of which frequently metastasize to the brain. The tumor specificity of LP-184 is driven by expression levels of PTGR1, and Lantern's RADR® analysis indicates that such expression levels are retained in brain mets of these primary tumors.\nThe virtual poster will be presented by Lantern Pharma in collaboration with Johns Hopkins School of Medicine and the Kennedy Krieger Institute and will describe positive preclinical data demonstrating the effectiveness of LP-184 treatment in brain mets cell models derived from patient lung, skin, and breast cancers. The poster will also show that in an in vitro model of brain mets from lung cancer, LP-...